Darzalex access in India: the CDSCO named-patient pathway
How patients in the Republic of India legally obtain Darzalex (daratumumab) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Ask about Darzalex in India
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Patients in India access Darzalex (daratumumab) for multiple myeloma in newly diagnosed and relapsed/refractory settings in combination regimens, and light-chain amyloidosis, under the FDA label through the CDSCO named-patient pathway, a Central Drugs Standard Control Organisation-administered mechanism that allows an Indian-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and how to get a written quote.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Reserved for you.
How Darzalex reaches patients in India
Darzalex (daratumumab IV, FDA-approved 2015; Darzalex Faspro SC, FDA-approved 2020; Janssen, anti-CD38 monoclonal antibody) is partially registered with CDSCO through Janssen's Indian affiliate and appears on the SUGAM database at cdscoonline.gov.in for selected presentations. Where the prescribed presentation, vial strength, FDA-label combination indication (for example D-VRd induction for newly diagnosed transplant-eligible myeloma per the PERSEUS expansion), or the SC Faspro form is not locally stocked, Indian patients access Darzalex via Form 12-A personal-use import under Rules 36 and 36A of the Drugs and Cosmetics Rules 1945; CDSCO issues Form 12-B typically within one to two working days when documentation is complete per cdsco.gov.in/consumer/Drugs-for-Personal-Use. Hospital-led imports for the named patient use CT Form-16 under the New Drugs and Clinical Trials Rules 2019. The Darzalex-specific clinical justification must document myeloma stage (ISS or R-ISS), prior lines of therapy where applicable, intended combination backbone (bortezomib plus lenalidomide plus dexamethasone, or others), infusion-related-reaction premedication plan for IV daratumumab, or the SC dosing schedule for Faspro. Cold-chain handling (2 to 8 degrees Celsius) is documented in the application. CDSCO Form 12-B is single-consignment; oncology cycles re-file per supply window.
Where Darzalex is administered in India
Darzalex IV requires infusion-capable day-care medical oncology or haematology with slow first-infusion protocols and pre-medication; Faspro SC requires ambulatory injection capacity with monitoring.
What Darzalex costs in India
Medicine price: quote on request. You get a written quote for your case before you commit. NPPA's database at nppaindia.nic.in does not list daratumumab under a Drug Price Control Order ceiling as of 2026-05-31. Where the prescribed Faspro SC form is needed but only the IV is locally stocked, Form 12-A import is the bridge.
Funding and access barriers for Darzalex in India
Multiple myeloma in India has an estimated age-standardised incidence approximately 1.2 to 1.5 per 100,000 per year. Public-sector funding: Rashtriya Arogya Nidhi (RAN) at mohfw.gov.in RAN page provides financial assistance up to a defined ceiling for BPL patients treated at designated government super-specialty hospitals. Medicine price: quote on request. You get a written quote for your case before you commit. State schemes (Tamil Nadu CMCHIS, Kerala KASP, Karnataka Ayushman Bharat-Arogya Karnataka, Andhra Aarogyasri) include selected myeloma packages with state-specific drug lists. Private insurance: standalone health insurers and general insurers increasingly cover daratumumab on higher-tier individual and corporate group policies subject to step-therapy and prior-authorisation criteria; IRDAI does not publish a national standard for NPP-imported drug coverage. Janssen India compassionate-access programmes have historically been a meaningful pathway for myeloma patients; eligibility is means-tested. The Form 12-B cold-chain import experience is operationally well-established for biologics into the major Indian air-cargo hubs.
Recent regulatory and access news for Darzalex
FDA approved (July 2024) Darzalex Faspro plus bortezomib, lenalidomide, and dexamethasone (D-VRd) for newly diagnosed multiple myeloma in transplant-eligible adults based on the PERSEUS trial, establishing a daratumumab-containing quadruplet as the new induction standard; the approval letter is at accessdata.fda.gov/scripts/cder/daf. FDA expanded the Faspro label (August 2024) to high-risk smouldering multiple myeloma. CDSCO Notifications at cdsco.gov.in/Notifications has issued routine periodic notifications on biologic-product registration timelines but no Darzalex-specific bulletin over the last 12 months as of 2026-05-31. NPPA continues quarterly Drug Price Control Order ceiling updates; no daratumumab ceiling has been added.
Where Reserve Meds fits in Darzalex cases
Reserve Meds is a US-based digital health company. We do not replace your treating physician, we do not replace CDSCO, and we do not replace your dispensing pharmacy. For Darzalex specifically, we orchestrate supply through a US-licensed pharmaceutical wholesale partner, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into India, and give you one point of contact through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Darzalex case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the CDSCO application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the case coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Rule 36 personal import or Form 12A institutional use applies.
Next step
If your Indian physician has prescribed Darzalex and you are weighing the cross-border route, the next step is a short intake. We reply within one business day, then send a documentation checklist to your doctor.
Reserved for you.